Home
About
Investors
- Investment Philosophy
- Client Portal
Corporates
Listed
Unlisted
News
Contact
Newsletter
Client Portal

Sateva Acquisition Progress

Jan 21, 2021

ASX News K2Fly

Send
Share
Share

Related Posts

Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

Jul 21, 2022 |

ASX News, Incannex Healthcare (ASX:IHL)

Nyrada Inc – Cholesterol-Lowering Program Preclinical Development Update

Apr 11, 2023 |

ASX News, Nyrada Inc (ASX:NYR)

NYX-PCSK9i Efficacy Study Published in Journal of Lipid Research

Oct 10, 2022 |

ASX News, Nyrada Inc (ASX:NYR)

Incannex Completes Acquisition of APIRx Pharmaceuticals to Aggregate the World’s Largest Portfolio of Patented Medicinal Cannabinoid Drug Formulations

Aug 5, 2022 |

ASX News, Incannex Healthcare (ASX:IHL)

GET INVESTMENT OPPORTUNITIES OR
RAISE CAPITAL

Contact Us

Home
About
Investors
- Investment Philosophy
Corporates

Listed
Unlisted

Latest News
Contact

CANARY CAPITAL PTY LTD

ABN 18 618 657 640
CAR number 1254859
Of BR Securities Australia Pty Ltd
Holder of AFSL 456663
Level 5/20 Bond St,
Sydney NSW 2000,
AUSTRALIA

P: (02) 9133 1325

Privacy Policy
Terms of Service
Disclaimer
Financial Services Guide

© 2024 Canary Capital | Web Development by Argon